5 Anti-Aging Benefits of Metformin

Metformin is a longstanding diabetes medication now studied for its potential anti-aging benefits, including effects on cancer risk, mortality, cognitive function, and inflammation.

Research suggests Metformin activates longevity pathways and genes, which may help lower the risk of several age-related conditions. Below, we list age-related diseases and corresponding evidence that has shown the positive impact of Metformin on these conditions.

Key Takeaways

• Metformin is associated with reduced risk of several cancers, including colon, pancreatic, and gastroenterological cancers, in multiple studies
• A UK study found type 2 diabetes patients taking Metformin lived longer than a matched non-diabetic control group over 5 years
• Metformin reduced diabetes onset risk by 31% in a large-scale trial and showed equal effectiveness in men and women
• Research suggests Metformin may lower inflammatory markers in the blood, an area of active interest for longevity researchers
• Studies have connected Metformin use to reduced risk of cognitive decline in older adults, with more research ongoing

Metformin Anti-Aging Benefits at a Glance

Benefit Area	Key Finding	Evidence Type	Population Studied
Cancer risk	Associated with lower cancer mortality compared to non-users	Observational study	1,300 patients (Netherlands)
Overall mortality	Type 2 diabetes patients on Metformin outlived a matched non-diabetic group over 5 years	Cohort study	78,000 patients (UK)
Diabetes prevention	Reduced diabetes onset risk by 31%, equally in men and women	Randomized trial	Large-scale, multi-year study
Cardiovascular health	Reduced macrovascular disease and cardiovascular mortality in both diabetic and non-diabetic patients	Randomized, placebo-controlled trial	390 patients
Cognitive function	Associated with decreased risk of cognitive impairment vs. thiazolidinediones over longer use	Observational study	67,731 adults over 65 (US)
Inflammation	May lower inflammatory markers including CRP and TNF-α, regardless of diabetes status	Multiple studies	Mixed populations

Does Metformin Reduce Cancer Risk?

Overall, we are more likely to face health challenges as we age. Cancer is one of those possible challenges. However, Metformin may have anti-cancer properties that could reduce the likelihood of being diagnosed with numerous forms of cancer, including:

• Reduced risk of colon or pancreas cancers
• Reduced incidences of gastroenterological cancers
• Decreased all-cause and prostate-cancer specific mortality

A Netherlands study of 1,300 patients also notes “Metformin use was associated with lower cancer mortality compared with non users.”

Can Metformin Reduce Overall Mortality?

A 2014 UK study compared 78,000 people with type 2 diabetes to a matched control group of 78,000 people without diabetes. Patients with type 2 diabetes who were taking Metformin had a longer survival rate than the non-diabetic control group over a 5-year period.

Does Metformin Help Prevent Diabetes?

Metformin may help reduce the risk of developing type 2 diabetes, particularly in people who are already at higher risk. In the large, multi-year Diabetes Prevention Program, Metformin was shown to reduce diabetes risk by 31% compared with placebo. The study also found that Metformin was similarly effective in men and women. Metformin primarily works by improving insulin sensitivity and reducing the amount of glucose the liver releases into the bloodstream, helping the body manage blood sugar more effectively. While Metformin is not a guarantee against developing diabetes, this research suggests it may be a useful tool alongside healthy lifestyle habits for certain people at increased risk.

Does Metformin Reduce Cardiovascular Risk?

A study of 390 patients in a randomized, placebo-controlled trial in 2009 concluded that Metformin reduced the risk of macrovascular disease. This study also included a 4.3-year follow-up and further concluded that Metformin can markedly reduce cardiovascular mortality. The study also showed that Metformin can reduce the incidence of cardiovascular events in both diabetic and non-diabetic patients with coronary heart disease. Researchers believe part of this benefit may come from how Metformin interacts with the vascular wall, potentially reducing oxidative stress and calming pro-inflammatory signaling within blood vessel cells, though the exact mechanism is still being studied. Longer-term follow-up data from the Diabetes Prevention Program, a large multi-year study, also found lower rates of coronary artery calcium buildup, a marker of atherosclerosis, in the Metformin group compared to placebo. This effect appeared particularly in men within that study, and researchers are continuing to look into whether similar results hold across broader populations.

Can Metformin Reduce the Risk of Cognitive Impairment?

Researchers studied 67,731 non-demented, non-diabetic adults over age 65 from January 2004 to December 2009. The study concluded that diabetes is associated with an increased risk of dementia. Among participants given sulfonylureas or Metformin instead of thiazolidinediones for a longer period of time, that risk was reduced. The study also determined that Metformin showed a marked decrease in cognitive impairment.

Does Metformin Reduce Inflammation?

Chronic low-grade inflammation is increasingly viewed as a driver of aging itself, sometimes called inflammaging. This is the idea that inflammation can quietly build up in the body over decades, even without a specific illness or infection, and may contribute to many age-related conditions over time. Research suggests Metformin may help lower several inflammatory markers in the blood, including CRP and TNF-α, and some studies indicate this effect may occur whether or not someone has diabetes. One proposed mechanism involves Metformin’s activation of AMPK, an enzyme that helps cells sense and manage energy. Activated AMPK may in turn suppress NF-kB, a protein complex considered a key driver of inflammatory signaling throughout the body. In one large cohort study of people with type 2 diabetes, researchers observed reductions in the neutrophil-to-lymphocyte ratio, a marker of systemic inflammation, after 8 to 16 months of Metformin use. While the exact mechanisms are still being studied, researchers are now looking at whether these anti-inflammatory effects extend meaningfully to adults without diabetes, an open question that continues to interest longevity researchers.

How Does Metformin Interact With Exercise?

Some research has looked at how Metformin interacts with exercise, since both are associated with healthy aging. Some early research comparing people who exercised with and without Metformin has suggested strength gains may be similar between groups, though the Metformin group tended to gain somewhat less muscle mass, a tradeoff worth discussing with a clinician alongside other Metformin side effects. Researchers have suggested this combination may still support beneficial changes in aging-related pathways beyond muscle alone. Longevity researcher David Sinclair has pointed to this research as evidence that pairing Metformin with exercise may support healthy aging without meaningfully limiting fitness gains.

Can Metformin Support Brain Health?

New research suggests Metformin may also help support brain health as we age. A 2024 primate study found that Metformin appeared to slow biological aging across several tissues, including the brain, and was associated with better preserved cognitive function. Earlier studies in people with type 2 diabetes have similarly suggested Metformin may help lower the risk of cognitive decline. One proposed mechanism is that Metformin activates an enzyme called AMPK in brain tissue, which may help clear cellular debris and lower neuroinflammation, two processes linked to cognitive aging. Supporting this idea, a meta-analysis in people with diabetes found Metformin use was associated with reduced incidence of cognitive impairment and clinically diagnosed Alzheimer’s disease, though the authors note this population-level association does not yet establish causality in non-diabetic adults. While more research is needed to confirm these effects in the general population, brain health has become one of the most actively watched areas in Metformin longevity research.

*Metformin has not been approved by the FDA for these uses, but there are multiple studies that have shown these benefits.

Note: The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.